Zolmitriptan

• Catalog No.: DB00315
• CAS Number: 139264-17-8
• M. F.: C16H21N3O2
• M. W.: 287.35684

SYNONYMS

• IUPAC name: (4R)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
• IUPAC Traditional name: zolmitriptan
• Brand Name: AscoTop; Zomig Rapimelt; Zomigon; Zomig
• Synonyms: ZMT; zolmitriptan

DATABASE IDS

• CAS Number: 139264-17-8

PROPERTIES

• Hydrophobicity(logP): 1.6

DETAILS

Description (English)

• Drug Groups: approved; investigational
• Description: Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia]
• Indication: For the acute treatment of adult migraine with or without auras.
• Pharmacology: Zolmitriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists, and has only a weak affinity for 5-HT_1A, 5-HT_5A, and 5-HT₇ receptors and no significant affinity or pharmacological activity at 5-HT₂, 5-HT₃ or 5-HT₄ receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. There have been three metabolites identified: indole acetic acid, N -oxide, and N-desmethyl metabolites. However, the N-desmethyl is the only active metabolite.
• Absorption: Mean absolute oral bioavailability is approximately 40%. Food has no affect on the rate and extent of absorption.
• Half Life: The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.
• Protein Binding: 25%
• Distribution: * 8.4±3.3 L/kg
• Clearance: * 25.9 mL/min/kg
• References: Pascual J: [Mechanism of action of zolmitriptan] Neurologia. 1998 Oct;13 Suppl 2:9-15. [Pubmed] ; Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

REFERENCES

• Pascual J: [Mechanism of action of zolmitriptan] Neurologia. 1998 Oct;13 Suppl 2:9-15. Pubmed
• Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. Pubmed